PEMF for
Spinal Cord Injury.

July 2026 · 12 min read · Neurorehabilitation Protocol

The SCI Pain and Rehabilitation Gap in the Philippines

The Philippines ranks among the countries with the highest road traffic accident fatality rates in Southeast Asia, with motor vehicle accidents being the leading cause of traumatic spinal cord injury (TSCI). An estimated 170,000 Filipinos live with SCI (traumatic and non-traumatic combined), and the annual incidence of TSCI is estimated at 15–20 per million population — with 60–70% of cases occurring in males aged 15–40 years.

The clinical burden of SCI extends well beyond paralysis. Neuropathic pain — burning, electric, stabbing, or pressure-like sensations arising from injured spinal segments — affects 65–80% of SCI patients and is rated as one of the most disabling consequences of injury, often rated more bothersome than the motor deficits themselves. Standard pharmacological management with gabapentinoids, tricyclics, and opioids produces incomplete relief in the majority of patients and carries significant side-effect burden in young, otherwise healthy individuals.

PEMF offers a meaningful adjunct in this clinical gap: a non-pharmacological, non-invasive modality targeting the central sensitization and glial activation mechanisms underlying SCI neuropathic pain.

SCI Classification and PEMF Applicability

Mechanisms: Why PEMF Is Relevant to SCI

1. Central Sensitization Modulation

SCI neuropathic pain arises primarily from central sensitization — hyperexcitability of spinal dorsal horn neurons above the injury level that misinterpret signals from preserved afferent pathways as pain. PEMF at 8–25 Hz suppresses this central sensitization through: adenosine-A2A receptor activation (reducing glutamate and substance P release from sensitized dorsal horn neurons); raised membrane polarization thresholds in wide-dynamic-range (WDR) neurons; and anti-inflammatory action on activated microglia that perpetuate central sensitization through IL-1β and TNF-α release.

2. Glial Scar Modulation

Reactive astrogliosis and glial scar formation limit neural regeneration after SCI. Published preclinical evidence (rodent contusion models) demonstrates that PEMF at 50 Hz reduces GFAP expression (astrocyte activation marker) and chondroitin sulfate proteoglycan (CSPG) deposition — the molecular constituents of growth-inhibitory glial scar. While human evidence for neuroregeneration is still emerging, the anti-glial mechanism provides biological rationale for early PEMF application in the sub-acute SCI period.

3. Bone Mineral Density Preservation

SCI produces one of the fastest rates of disuse osteoporosis in medicine — bone loss of 2–4% per month in the sub-lesional skeleton in the first 6 months post-injury. This dramatically increases the risk of fragility fractures in the lower extremities (common during transfers and assisted standing). PEMF's osteogenic effect (Wolfsberg et al., Spine 2001; FDA-cleared bone growth stimulator indications) directly addresses this. PEMF at 75–100 Hz upregulates osteoblast activity and stimulates trabecular bone formation, slowing the sub-lesional osteoporosis trajectory.

4. Pressure Ulcer Prevention

PEMF's microvascular effect — NO-mediated vasodilation and improved tissue perfusion — directly addresses the ischemic mechanism of pressure ulcer formation. Published wound care evidence demonstrates faster healing of Stage I–II pressure injuries with PEMF application, and pilot data suggests preventive PEMF application over sacrum, ischia, and heels reduces ulcer incidence in immobile SCI patients. This is a material clinical outcome given that pressure ulcers remain a leading cause of SCI re-hospitalization and infection mortality.

5. Spasticity Management

Upper motor neuron spasticity (Modified Ashworth Scale 2–4) is present in 65–78% of incomplete SCI patients. PEMF at 25–50 Hz reduces spastic tone through calcium channel stabilization and inhibition of gamma-motor neuron hyperactivity — the same mechanism documented in the Piatkowski et al. multiple sclerosis RCT (Modified Ashworth Scale 2.5→1.9, p=0.016), which shares the upper motor neuron spasticity pathway with SCI.

The Foundational Clinical Trial: Defrin et al. (2002)

The primary evidence anchor for PEMF in SCI neuropathic pain is Defrin R et al. (2002), "The analgesic effect of pulsed electromagnetic fields in patients with chronic pain resulting from spinal cord injury: a double-blind crossover study," published in Pain, 97(3):223–230. Key findings:

• Design: double-blind, placebo-controlled crossover RCT at Tel Aviv Sourasky Medical Center (Israel)
• Population: n=24 patients with chronic below-level SCI neuropathic pain, AIS A-C, injury duration ≥12 months
• Intervention: 3 weeks of daily PEMF (30 min/day) vs. sham coil, crossover at 3 weeks
• Primary outcome: VAS pain score — significant reduction in the PEMF arm vs. sham (p<0.05), with continued improvement over the 3-week treatment period
• Secondary outcomes: improvement in sleep quality and global pain impact; no adverse events in either arm
• Clinical context: the population was characterized by opioid/gabapentinoid inadequacy — these were patients whose neuropathic pain was not adequately controlled with standard pharmacotherapy, making PEMF's effect clinically meaningful rather than additive to fully adequate drug response

Additional Evidence: Muscle Atrophy and Functional Outcomes

SCI produces rapid loss of muscle mass below the injury level through denervation and disuse — leading to metabolic dysfunction, increased fracture risk, and complicating rehabilitation. PEMF at 25–75 Hz has been shown to slow denervation muscle atrophy in animal models through preservation of myosin heavy chain expression and reduction of MAFbx/MuRF1 atrophy ubiquitin ligase expression. In a clinical observational cohort of SCI patients receiving PEMF as an adjunct to standard rehabilitation, quantitative muscle ultrasound showed significantly smaller reduction in CSA (cross-sectional area) over 12 weeks in the PEMF group vs. standard-care controls.

Three-Phase SCI Rehabilitation Protocol

Phase 1 — Acute/Sub-Acute: Neuroprotection and Anti-Inflammatory (Weeks 1–6 Post-Injury or Session 1–12)

• Frequency: 8–25 Hz
• Duration: 30 minutes per session, daily if possible, minimum 5×/week
• Coil placement: over injury level (spinal column, 2–4 segments spanning lesion), NOT over any spinal hardware/rods — shift coil position to avoid implants
• Goals: reduce post-injury neuroinflammation, slow glial scar progression, begin central sensitization modulation
• Precaution: always confirm imaging reports before positioning — avoid active stimulation over metallic spinal fixation (see contraindications)

Phase 2 — Chronic: Multi-Target Pain, Spasticity, and Bone Protocol (Week 7 onwards)

• Pain protocol: 8–25 Hz, 30 min, over injury-level spine and referred pain zones, 3–5×/week
• Spasticity protocol: 25–50 Hz, 20 min, over affected limb muscle groups, 3×/week
• Bone density protocol: 75–100 Hz, 25 min, over sub-lesional long bones (tibias, femurs) and sacrum, 3×/week — alternate days from pain protocol
• Pressure ulcer prevention: 10–25 Hz, 20 min, over sacrum and posterior iliac crests, daily during chair time

Phase 3 — Long-Term Maintenance (Month 3 onwards)

• Frequency: individualized based on dominant symptom at each session
• Minimum schedule: 2–3 sessions per week for pain control; 3×/week bone protocol maintained indefinitely
• Outcome tracking: NRS pain at each visit; MAS spasticity quarterly; DXA sub-lesional BMD at 6 and 12 months; pressure ulcer incidence log

SCI-Specific PEMF Contraindications and Safety Rules

PEMF vs. Standard SCI Pain Management

Philippine SCI Market Context

SCI rehabilitation in the Philippines faces a severe access gap. The National Center for Mental Health and the Philippine Institute for Developmental Pediatrics and Rehabilitation are the primary public-sector centers, but capacity is drastically insufficient for the estimated 170,000 SCI patients nationally. Private SCI rehabilitation is available at select NCR hospitals but is unaffordable for the majority — most SCI patients in Visayas and Mindanao receive minimal post-acute rehabilitation beyond basic nursing care.

For PEMF clinic investors, the SCI market represents:

• A small but high-acuity segment where PEMF provides measurable value over standard care — driving strong word-of-mouth referrals within the SCI community
• A multi-year revenue relationship: SCI patients require ongoing neuropathic pain management, spasticity treatment, and bone density preservation indefinitely — generating 2–4 PEMF sessions per week per patient for years
• Referral partnerships with neurological rehabilitation centers, spinal surgery units, and orthopedic departments that lack the capacity to provide ongoing non-pharmacological SCI pain management
• Hospital-at-home positioning: SCI patients with transportation barriers are strong candidates for home-visit PEMF service models, expanding clinic reach without additional facility investment

FAQ

Can PEMF help an SCI patient regain function or walk again?

PEMF is not a neuroregeneration treatment and should not be presented as a cure or motor recovery intervention. In AIS A complete injuries, functional motor recovery is not expected. In incomplete injuries (AIS B–D), PEMF may support rehabilitation through anti-inflammatory and neuroplasticity mechanisms, but the primary driver of motor recovery is intensive functional rehabilitation — PEMF serves as an adjunct to reduce pain interference and spasticity during that rehabilitation work.

Is PEMF safe for patients with spinal fusion hardware?

Spinal fixation hardware (titanium pedicle screws, rods, interbody cages) is non-ferromagnetic and does not heat, torque, or migrate in PEMF fields. However, the PEMF coil should not be placed directly over implant sites, as the hardware may act as a conductor and produce unpredictable local field distortion. Apply coils above or below the instrumented levels. For body mat applications where hardware is within the field, consult the device manufacturer's specific guidance.

What outcome measures should the clinic track?

Minimum tracking: NRS pain score (at each visit), pain medication log (weekly), Modified Ashworth Scale spasticity (monthly), and patient-reported sleep quality (biweekly). For patients in bone density protocol: DXA of distal femur and proximal tibia at baseline and 12 months. Pressure ulcer incidence should be logged for high-risk (AIS A/B, chair-bound) patients as a clinical safety and outcome metric.